Silexion Therapeutics Corp SLXN
Set alert
0.15 USD 0.00 +2.04%
At close · Oct 30
0.15 0.00 +0.62%
After hours · Oct 30, 7:47 PM ET
0.1401 Day range 0.17
0.142 52-week range 33.14
- YTD
- -99.24%
- 1 year
- -99.56%
- Open
- 0.1424
- Prev close
- 0.1423
- Mkt cap
- 2.21M
- Vol
- 741.91K
- Avg vol
- 10.25M
- EPS
- -27.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1401
- High
- 0.17
- Forward P/E
- -3.95
- Beta
- -0.11
- Short ratio
- 0.23
- Inst. own
- 8.15%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.12
- 200-d avg
- 6.82
- 1y target
- 9.00
2Y chart
Events in this range
- Nov 1, 2024Rating: Maxim Group · — → Buy
- Nov 14, 2024Earnings: -18.27; estimate 0; surprise —%
- May 29, 2026Split: 1 for 10
Signals (69)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| RSI: Oversold | Aug 11, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 30, 2026 | 3 months ago |
| RSI: Oversold | Jul 29, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 23, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | May 12, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| RSI: Oversold | Apr 24, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 17, 2026 | 6 months ago |
| RSI: Oversold | Apr 13, 2026 | 6 months ago |
| RSI: Oversold | Mar 20, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 17, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 24, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 23, 2026 | 8 months ago |
| RSI: Oversold | Feb 23, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 19, 2026 | 8 months ago |
| RSI: Oversold | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 9, 2026 | 9 months ago |
| RSI: Oversold | Dec 30, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 18, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 19, 2025 | 11 months ago |
| RSI: Oversold | Nov 13, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 11, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 10, 2025 | 11 months ago |
| RSI: Oversold | Nov 4, 2025 | 12 months ago |
| MACD: Buy Signal | Sep 24, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 10, 2025 | 1 year ago |
| RSI: Oversold | Sep 9, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 25, 2025 | 1 year ago |
| SMA: Bearish | Aug 1, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 31, 2025 | 1 year ago |
| SMA: Bearish | Jul 29, 2025 | 1 year ago |
| SMA: Bullish | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 24, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 7, 2025 | 1 year ago |
| SMA: Bearish | Jun 11, 2025 | 1 year ago |
| SMA: Bullish | Jun 6, 2025 | 1 year ago |
| SMA: Bearish | Jun 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 4, 2025 | 1 year ago |
| SMA: Bullish | May 22, 2025 | 1 year ago |
| MACD: Buy Signal | May 22, 2025 | 1 year ago |
| MACD: Sell Signal | May 20, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 23, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 28, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 21, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 13, 2025 | 1 year ago |
| SMA: Bearish | Feb 3, 2025 | 1 year ago |
| SMA: Bullish | Jan 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 29, 2025 | 1 year ago |
| RSI: Oversold | Jan 21, 2025 | 1 year ago |
| SMA: Bearish | Jan 15, 2025 | 1 year ago |
| RSI: Overbought | Nov 29, 2024 | 1 year ago |
Key statistics
- Market cap
- 4.06M
- Enterprise value
- 16.46M
- Trailing P/E
- 0.00
- Forward P/E
- -3.95
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.54
- EPS (TTM)
- -13.22
- Beta
- -0.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -305.63K
- Total cash
- 2.78M
- Total debt
- 144.00K
- Return on equity
- -116.66%
- Shares outstanding
- 1.60M
- Short % of float
- 3.08%
- 50-day average
- 1.12
- 200-day average
- 6.82
Analyst view
Consensus: buy
Buy
Price target (mean) 9.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
SLXN Revenue — quarterly 0
SLXN Net income — quarterly -3.55M
SLXN EPS — quarterly -5.17
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -18.27 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 1, 2024 | Maxim Group | init | — | Buy |
About Silexion Therapeutics Corp
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- silexion.com
News
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Silexion Therapeutics Announces First Patient Dosed Phase 2/3 Clinical Trial Evaluating Lead Candidate, SIL204, In Patients With Locally Advanced Pancreatic Cancer
- Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
- Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Silexion Therapeutics To Raise $837K Via Exercise Of ~3.217M Series E Warrants At $0.2603/Share
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Silexion Therapeutics Announces Exercise of Warrants
Your note
Sign in to keep a note on SLXN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wildcat Capital Management, LLC | 0.79% | 113,428 | 286.97K | Sep 29, 2024 |
| HRT Financial LP | 0.07% | 9,997 | 25.29K | Sep 29, 2024 |
| Virtu Financial LLC | 0.02% | 2,962 | 7.49K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.01% | 1,680 | 4.25K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 1,673 | 4.23K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 587 | 1.49K | Oct 30, 2024 |